沙利度胺对多发性骨髓瘤骨髓间充质干细胞凋亡及白介素-6的影响  

Effect of thalidomide on apoptosis of bone marrow mesenchymal stem cells and interleukin-6 in multiple myeloma

作　　者：吴元庭 任莉[2] 吴海英 蒋慧芳[2] 苏传勇[2] 陶叠红 郭淑萍 WU Yuanting;REN Li;WU Haiying(The Second Medical College,Zhejiang University of Traditional ChineseMedicine,Hangzhou 310053,China)

机构地区：[1]浙江中医药大学第二临床医学院,浙江杭州310053 [2]浙江省立同德医院血液科

出　　处：《全科医学临床与教育》2018年第3期253-255,259,共4页Clinical Education of General Practice

基　　金：浙江省医药卫生科技项目(2014KYA028);浙江省中医药科技计划(2015AZ021)

摘　　要：目的观察沙利度胺对多发性骨髓瘤骨髓间充质干细胞(BMMSCs)凋亡及白介素-6(IL-6)的影响。方法采用细胞凋亡检测试剂盒双染色(Annexin V-FITC/PI)检测细胞凋亡。采用实时荧光定量PCR技术(RTq PCR)检测经沙利度胺作用于BMMSCs后IL-6、白介素-1β(IL-1β)及干细胞因子m RNA(SCF m RNA)的水平表达。结果 BMMSCs的分离鉴定培养,细胞形态学提示为长梭状细胞,说明分离得到较纯的BMMSCs。25 ng/ml、50 ng/ml、100 ng/ml沙利度胺对BMMSCs作用处理48 h,与0 ng/ml组比较,仅50 ng/ml沙利度胺组的凋亡率明显增加,差异有统计学意义(t=1.12,P<0.05)。RT-q PCR检测IL-6、IL-1β、SCF结果显示,0~100 ng/ml的沙利度胺处理BMMSCs 48 h后,仅100 ng/ml沙利度胺组的IL-6明显降低,差异有统计学意义(t=1.27,P<0.05)。结论50 ng/ml沙利度胺可增加BMMSCs凋亡,100 ng/ml沙利度胺能降低BMMSCs的IL-6。] Objective To observe the influence of thalidomide on apoptosis of bone marrow mesenchymal stem cells（BMMSCs）and interleukin -6（IL-6）in patients with multiple myeloma. Methods Cells apoptosis was detected by AnnexinV- FITC/PI double staining. After thalidomide acted on BMMSCs,the IL- 6,IL- 1β and SCF mRNA expressions weredetected by RT-qPCRs. Results The cell morphology showed that the BMMSCs are long spindle cells,which is indicatingthat the pure BMMSCs were separated. The BMMSCs were dealt with different concentrations thalidomide including 25 ng/ml,50 ng/ml,and 100 ng/ml for 48 h. Compared with the 0 ng/ml group,the apoptotic rate of the 50 ng/ml thalidomide group wassignificantly increased（t=1.12,P〈0.05）. The results of RT-qPCR showed that the IL-6 of the 100 ng/ml thalidomide groupwas significantly decreased when compared with the blank group（t=1.27,P〈0.05） . Conclusion Thalidomide withconcentration of 50 ng/ml increase BMMSCs apoptosis,and 100 ng/ml thalidomide reduce IL-6 level in BMMSCs.

关 键 词：沙利度胺 多发性骨髓瘤 骨髓间充质干细胞 细胞因子 

分 类 号：R733.3[医药卫生—肿瘤]